Creative Medical Technology Reports Acquisition of 80% of BioDefense

What Happened
Creative Medical Technology Holdings, Inc. announced on September 24, 2026 that it entered into a Stock Purchase Agreement with Creative Acquisition Corp. (CAC) to buy 4,000,000 shares of BioDefense, Inc. The Company paid $200,000 in cash and issued 1,000,000 shares of its own common stock as consideration. After the transaction, Creative Medical owns 16,000,000 shares (80%) of BioDefense and CAC owns 4,000,000 shares (20%).

Key Details

• Transaction date: September 24, 2026.
• Consideration paid by Creative Medical: $200,000 cash + 1,000,000 shares of Creative Medical common stock.
• Post-transaction ownership: Creative Medical — 16,000,000 shares (80%); CAC — 4,000,000 shares (20%).
• Related-party note: Timothy Warbington is President & CEO of Creative Medical and Chairman & CEO of CAC; he indirectly owns all outstanding shares of CAC. The shares issued to CAC were sold in a private placement under Section 4(a)(2) of the Securities Act.

Why It Matters
The deal makes Creative Medical the majority owner (80%) of BioDefense, which could affect how BioDefense’s results are reported or consolidated in Creative Medical’s future financial statements. Investors should note the transaction involved issuance of 1,000,000 Creative Medical shares (dilution impact) and a $200,000 cash outlay, and that the counterparty (CAC) is controlled by the Company’s CEO, which is a related-party transaction disclosed in the filing.